Chronic Lymphocytic Leukemia (CLL) treatment often leads to adverse drug reactions (ADRs) and drug-drug interactions (DDIs), significantly impacting patients’ quality of life (QoL). To address the challenges in managing ADRs/DDIs, the PEDRO platform was developed to enhance communication between healthcare professionals (HCPs) managing patients with CLL in real-world healthcare settings and experts with significant research profiles in CLL. This paper presents the PEDRO platform built to provide a secure, scalable, and user-friendly solution for peer-to-peer (P2P) support in ADR/DDI management.
PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL / Timamopoulos, C., Chatzikonstantinou, T., Panos, B., Scarfo', L., Ghia, P., Kostas, S., Anastasia, F., Achilleas, C., Alexandros, R., Kalliopi, K., Natsiavas, P.. - 328:(2025), pp. 313-317. [10.3233/SHTI250726]
PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL
Scarfo' L.;Ghia P.;
2025-01-01
Abstract
Chronic Lymphocytic Leukemia (CLL) treatment often leads to adverse drug reactions (ADRs) and drug-drug interactions (DDIs), significantly impacting patients’ quality of life (QoL). To address the challenges in managing ADRs/DDIs, the PEDRO platform was developed to enhance communication between healthcare professionals (HCPs) managing patients with CLL in real-world healthcare settings and experts with significant research profiles in CLL. This paper presents the PEDRO platform built to provide a secure, scalable, and user-friendly solution for peer-to-peer (P2P) support in ADR/DDI management.| File | Dimensione | Formato | |
|---|---|---|---|
|
SHTI-328-SHTI250726.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
650.23 kB
Formato
Adobe PDF
|
650.23 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
